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Abstract
Transfer of full-length genes including regulatory elements has been the preferred gene therapy strategy for
clinical applications. However, with significant drawbacks emerging, targeted gene alteration (TGA) has recently
become a promising alternative to this method. By means of TGA, endogenous DNA repair pathways of the cell
are activated leading to specific genetic correction of single-base mutations in the genome. This strategy can be
implemented using single-stranded oligodeoxyribonucleotides (ssODNs), small DNA fragments (SDFs), triplex-
forming oligonucleotides (TFOs), adeno-associated virus vectors (AAVs) and zinc-finger nucleases (ZFNs). Despite
difficulties in the use of TGA, including lack of knowledge on the repair mechanisms stimulated by the individual
methods, the field holds great promise for the future. The objective of this review is to summarize and evaluate
the different methods that exist within this particular area of human gene therapy research.
Introduction
In the middle of the nineties, the field of targeted gene
alteration (TGA) emerged as a possible method to cor-
rect diseases caused by single-base mutations [1,2]. Initi-
ally, the approach focused on stimulating the endogenous
gene repair mechanisms using various single- or double-
stranded oligonucleotides. These are complementary to
part of the targeted gene except for one mismatched base
specifically located at the site of the endogenous muta-
tion. Upon cellular introduction these molecules will
interact with the targeted gene sequence by different
mechanisms. The mismatch is then recognized by com-
ponents of the gene repair pathways, which subsequently
can be stimulated to correct the mismatch by the use of
the introduced targeting molecule [3-6].
Using TGA, mutated genes can be targeted and cor-
rected without interfering with the endogenous promo-
ter as well as enhancer/silencer elements and reading
frames [7]. Such an impact has otherwise been seen
with certain aspects of gene therapy introducing a com-
plete gene sequence including all its associated elements
[8,9]. Several methods have been developed in order to
optimize and effectively implement the TGA strategy
in vitro as well as in vivo. These methods all constitute
different structures of targeting molecules, pathways of
integration and gene repair pathways stimulated, result-
ing in variable success rates [4,10-12].
Mammalian gene repair pathways
Mammalian cells utilize a variety of genetic repair path-
ways to ensure genomic stability of the genome. Under-
standing these pathways is essential for the further
optimization of TGA [13-16]. A brief introduction to the
pathways including their most central molecular factors is
provided here (Figure 1). For detailed reviews see [17-23].
Mismatch Repair (MMR)
The mismatch repair system (MMR) mainly corrects
replication errors such as A-G and T-C mismatches [18].
It has been extensively studied both in prokaryotes and
in mammalian cells, but for simplicity the following
description will mainly focus on the mammalian
homologues.
The recognition of mismatches in the mammalian MMR
system (Figure 1A) is conducted by heterodimers of Msh
(MutS homologue) proteins [24]. The Msh2:Msh6 hetero-
dimer (hMutSa) recognizes base:base mismatches and
small insertion/deletion loops, whereas the Msh2:Msh3
heterodimer (hMutSb) recognizes 2-10 nucleotide inser-
tion/deletion loops [25]. hMutSa-mediated mismatch
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sis put on the mechanism conducted by hMutSb.H o w -
ever, several similarities exist between the pathways [24].
hMutSa recognizes the mismatched base and binds to the
damaged DNA strand, hereby recruiting hMutLa (hMlh1:
hPms2 heterodimer) [19,24]. With the exchange of ADP
for ATP, the hMutSa complex slides along the DNA
strand causing hPms2-induced nicks on either side of the
mismatch [17,19]. This enables entry of the exonuclease,
hExoI, onto the 3’-end of the damaged strand, where it
removes ~150 bases including the mismatch, after which
replication protein A (RPA) is recruited to protect the
newly exposed ssDNA [17]. DNA polymerase δ binds in
association with its processivity factor proliferating cell
nuclear antigen (PCNA) which is loaded onto the pro-
cessed DNA by replication factor C (RFC) [24,25]. A new
DNA strand is subsequently re-synthesized after which
DNA ligase I joins the ends [17,19].
Nucleotide Excision Repair (NER)
The nucleotide excision repair pathway (NER) (Figure 1B)
primarily corrects bulky adducts and pyrimidine dimers
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Figure 1 Components involved in mammalian repair pathways. A: In mismatch repair (MMR), hMutSa recognizes the DNA damage whereby
hMutLa is recruited resulting in nicks on either side of the mismatch. Human exonuclease I (hExoI, 5’®3’ activity) excises the mismatch and its
flanking sequences after which DNA polymerase (3’®5’ activity), along with PCNA and RFC, re-synthesizes a new DNA strand. B: In nucleotide
excision repair (NER), the XPC complex recognizes the DNA damage causing the recruitment of the TFIIH complex, which unwinds the DNA to
an open complex. XPA binds the damaged DNA strand after which endonucleases, XPG and XPF-ERCC1, excise the mismatch and DNA
polymerase, with PCNA and RFC re-synthesizes the DNA strand. C: In homology-directed repair (HDR), the DSB is bound by the MRN complex
recruiting CtIP and hExo, the latter of which excise nucleotides surrounding the break. Rad51 initiates homology search and when a
homologous DNA donor is found, the DSB is repaired through Holliday junction formation and resolution. D: In non-homologous end-joining
(NHEJ), the Ku complex recognizes the DSB leading to a simultaneous recruitment of DNA-PKCS, XRCC4:LigIV and XLF. The exchange of these
factors drives the ligation of the non-homologous ends. Artemis nuclease, DNA polymerases μ and l and other protein factors can be involved
if the DNA ends are not directly compatible. See text for further details.
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Page 2 of 14caused by e.g. UV light [26]. Damage recognition is carried
out by the XPC complex consisting of XPC, HR23B and
Centrin-2, which binds to the non-damaged strand [20].
The TFIIH-complex, which is a heterodimer of 2 different
helicases XPD (5’®3’ activity) and XPB (3’®5’ activity)
attached to a cyclin-activated kinase (CAK) complex, is
recruited and unwinds the double-stranded DNA sur-
rounding the mutation [20,27,28]. An XPA-complex then
binds to the damaged DNA strand followed by the arrival
of an incision complex, consisting of the endonucleases
XPG and XPF-ERCC1 [20]. This causes the excision of
25-30 nucleotides, including the damaged DNA, after
which DNA polymerase δ (including PCNA) or DNA
polymerase ε re-synthesize the DNA strand. Eventually,
DNA ligase III re-joins the ends [20].
The recognition pathway involving the XPC-complex is
named global genome repair (GGR) and corrects mis-
matches in the entire genome [27]. A transcription-
coupled repair (TCR), which especially repairs actively
transcribed genes, also exists. The damage recognition of
this pathway involves the stalling of the RNA polymerase
followed by recruitment of signaling molecules like Cock-
ayne syndrome group A (CSA) and Cockayne syndrome
group B (CSB) proteins [28]. Apart from the recognition
step TCR functions as the GGR pathway [20].
Base Excision Repair (BER)
Base excision repair (BER) corrects DNA mismatches
caused by alkylation, deamination or oxidative damage
[29]. Recently, it was shown that this pathway can be
involved in one of the gene repair techniques (see single-
stranded oligodeoxyribonucleotides) described in this
review [30]. The DNA mismatch is recognized by DNA
glycosylases which flip the damaged base out of the DNA
helix and cleave it, creating an apurinic/apyrimidinic site
(AP site) [29]. The DNA strand is subsequently cleaved by
an AP endonuclease and an AP lyase creating a gap which
is filled by DNA polymerase b and ligated by DNA ligase
III [29]. A long-patch pathway of BER also exist where
PCNA, DNA polymerase δ and DNA ligase I are among
the proteins involved [29].
Homology-Directed Repair (HDR) and Non-Homologous
End-Joining (NHEJ)
Homology-directed repair (HDR) and non-homologous
end-joining (NHEJ) are redundantly used to correct
double-stranded breaks (DSBs) in the genome. Since
these breaks are some of the most dangerous DNA
damages occurring, these repair mechanisms play an
important role in maintaining the integrity of the
genome.
HDR repairs DSBs by the action of homologous
recombination (HR) between homologous sequences
using e.g. a sister chromatid as template (Figure 1C)
[23]. After binding of the Mre11-Rad50-Nbs1 (MRN)
complex, binding of CtIP is followed by human exonu-
clease I, hExoI, which trims the strands in a 5’-3’-direc-
ted manner. Replication protein A (RPA) is then
recruited to protect the exposed ssDNA, before Rad51
initiates a homology search. When a homologous
sequence has been detected, HR occurs through the for-
mation and resolution of a Holliday junction [23].
NHEJ is the predominant mammalian DSB-repair path-
way of the two, occurring at a ratio of approximately
1000:1 [31]. However, NHEJ re-ligates DNA ends without
any use of homology, thus causing it to be highly error-
prone [32]. The damage recognition factor of the NHEJ
pathway is the heterodimeric protein complex Ku con-
sisting of the two subunits, Ku70 and Ku86 (Figure 1D)
[33]. Ku binds the break-induced DNA ends leading to
the independent, but simultaneous, recruitment of DNA-
PKcs, XRCC4:LigIV and XLF [21]. These latter factors
are constantly exchanged with non-bound proteins,
hereby driving the NHEJ reaction where the newly
exposed DNA ends are ligated back together [21]. If the
two DNA ends are not directly compatible for ligation
several other protein factors, as e.g. Artemis nuclease,
facilitates the end-joining reaction [22].
It is currently unknown how the cellular decision on
using NHEJ or HDR is made. HDR seems to occur only
in cells that are in the S/G2 cell cycle phase, whereas
NHEJ does not seem to be phase-restricted, although
repairing all damages happening in the G1 phase [21,34].
In either case, the 5’®3’-resection of the exposed DNA
ends seem to play a pivotal role in the decision between
the two pathways [34]. Blunt DNA ends are preferably
corrected by NHEJ, whereas DNA ends corrected by
HDR are usually trimmed by hExoI [23,34]. Furthermore,
phosphorylation of the HDR-involved factor CtIP seems
to commit the repair to the HDR pathway, but whether
additional decisive factors exist is still debated [23].
Targeted gene alteration
As previously mentioned, several different techniques
can be used for altering mammalian genes through the
activation of gene repair pathways. Overall, they can be
divided into five categories, all of which will be dis-
cussed in the following. An overview of correlations
between gene repair pathways and TGA techniques is
illustrated in Figure 2 and a summary of important fea-
tures of the TGA methods is supplied in table 1.
The polymerase chain reaction frequently forms the
basis of assays involved in revealing effects of TGA-med-
iating methods and the reaction is furthermore used for
production of small DNA fragments (SDFs) [35]. How-
ever, PCR is an error-prone reaction and even using
highly accurate enzymes the DNA misincorporation fre-
quency during a PCR reaction is high (~0.0035-0.02/bp)
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unwanted mutations are introduced into the target gene
when the desired mismatch is being corrected. Further-
more, the risk of PCR artifacts caused by priming of the
corrective oligodeoxyribonucleotide (ODN) or SDF to
the DNA can lead to false positives and produce an
incorrect estimate of the correction efficiency [8,37]. Ear-
lier this lead to criticism especially of SDF- and ODN-
mediated gene targeting [37]. In order to avoid this,
novel protocols have recently been developed. These
include the use of analytical PCR-primers located outside
the region of SDF/ODN-homology as well as gel purifica-
tion of heat-denatured genomic target DNA [38-40].
Both of these methods contribute to an increased reliabil-
ity of PCR-based assays. However, the lack of standar-
dized, non-PCR-based assays of gene repair can make it
difficult to compare the different methods directly [8,39].
Next generation sequencing methods will probably be
used increasingly in order to document the repair fre-
quencies and the integrity of the genome.
Oligonucleotides
Single-stranded oligo-deoxyribonucleotides (ssODNs)
have been used for TGA. The structure of ssODNs is
simple and comprises a single-stranded DNA sequence
complementary to the target site except for a single mis-
matched nucleotide located centrally in the molecule
[3]. Phosphorothioate-conjugates as well as 2’-O-methy-
lated uracil bases can be used to create modified
ssODNs which exhibit high levels of stability through
resistance to e.g. endogenous RNase H activity [41,42].
The invasion mechanism of these oligonucleotides is
still unclear. However, several experimental results point
to the involvement of DNA replication in the incorpora-
tion process with replication forks destabilizing the
genomic nucleosome structure. Hereby, binding and
subsequent incorporation of the ssODN at or near the
replication fork - possibly as a “pseudo-Okazaki-frag-
ment” in the lagging strand - is enabled [43,44]. This
hypothesis is supported by evidence demonstrating that
cell cycle arrest in the S-phase occurs in ssODN-treated
cells. In these arrested cells cooperation between repli-
cation forks and the ssODN, including the search for
homology, have sufficient time to occur [12]. However,
the cell cycle arrest has been disputed and, if occurring,
it seems to be temporary [30,45]. In either case, a cellu-
lar need for prolonged S-phase may pose problems in
clinical applications with many in vivo targets under-
going only limited levels of replication and division [46].
Upon invasion, a 3-stranded heteroduplex is formed
between the ssODN and the double-stranded target site
[3,41]. Whether a correctional strand bias exists has
been discussed and in several instances antisense
ssODNs (i.e. ssODNs targeting the non-transcribed
strand) has been giving the highest correction efficien-
cies [4,9,47-49]. This strand bias originally led to the
conclusion that the transcription machinery and its
accessory factors invoke a steric hindrance on the
ssODN
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Figure 2 Currently known connections between TGA-techniques and mammalian repair pathways. Zinc finger nucleases (ZFNs, blue
lines) function via homology-directed repair with the potential involvement of mismatch repair and nucleotide excision repair pathways. Single-
stranded oligodeoxyribonucleotides (ssODNs, red lines) are believed to function via the nucleotide excision repair pathway with base excision
repair potentially also playing a role. Triplex-forming oligonucleotides (TFOs, green lines) function via the nucleotide excision repair pathway with
the possible participation of mismatch repair as well as non-homologous end-joining. Adeno-associated viruses (AAVs, brown lines) involve
homology-directed repair and potentially also mismatch repair and nucleotide excision repair. Small DNA fragments (SDFs, purple line) are
known to function via small fragment homologous recombination. See text for further details and references. Fully drawn lines refer to
connections supported by experimental evidence from several groups whereas dotted lines refer to less substantiated links.
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Page 4 of 14Table 1 Characteristics of TGA-mediating methods
Method: ssODNs SDF TFO AAV ZFN
Repair
pathways
involved
NER, HDR? (MMR and NHEJ are
suppressive)
SFHR NER, NHEJ? MMR? HDR? HDR, NHEJ HDR, NHEJ
Correction
efficiency
a
0.1-5% (somatic cells) ~0.1% (ESCs) 0.2-20% (somatic cells)
0.025% (ESCs)
0.1-1.5% (somatic cells) 9.86%-65% (somatic cells) ~1%
(ESCs and iPSCs)
~18-30% (somatic cells) 0.15-5%
(iPSCs + ESCs)
Advantages No integration of exogenous DNA,
synthesis, stable, reproducible results
Reproducible results,
potent episomal repair,
artifacts can be
circumvented
Synthesis, low toxicity, target specific,
functional in hHPCs, stable target-
complex formation
High efficiency and fidelity,
effective in vivo delivery, broad
cell type target field, low
pathogenicity
High efficiency, known repair
mechanism, normal cell cycle profiles,
low background integrations, target
silent genes
Disadvantages Unknown repair mechanism, limited
sequence size, PCR artifacts,
genotoxicity, cell replication
dependency
SFHR mechanism
unknown, depend on
HDR-like mechanism,
synthesis (PCR)
Unknown repair mechanism,
homopurine target restriction, G-C-
rich sequences, weak DNA-binding,
cellular death
Safety concerns, size limitation,
integration of exogenous DNA,
random integrations, cellular
death
Synthesis, off-target cleavage,
integration of exogenous DNA,
multiple transductions
Targeted
disease genes
Dystrophin
a-D-glucosidase
b-PDE
TYR
CFTR
DNA-PKcs
Dystrophin
b-globin
SMN1
b-globin COL1A1
COL1A2
FANCA
Fah
CFTR
CCR5
IL2Rg
CFTR
HoxB13
TYR
References
b [4,9,12,14,41,46-49,51,52,54,62,116,117] [4,8,35,39,40,63,64,118-121] [16,66-69,80,84,122] [4,11,31,54,85,88,90,92,93,123,124] [6,10,12,13,102,104,114,125-127]
a) Note that the correction efficiencies might not be directly comparable due to differences in determination (e.g. efficiency vs. efficacy, factoring in targeting frequency, in vivo vs. in vitro conditions, etc.).
b) References used to construct table.
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4transcribed strand complicating the binding of ssODNs
[50]. However, evidence show that the non-transcribed
strand can be biased even when targeting transcription-
ally silent genes [9]. This means that the transcription
machinery is not solely responsible, if at all, for the
strand bias seen with ssODNs and transcription-inde-
pendent factors must be involved in the process [9,49].
In addition, studies show that two identical mutations at
different locations of a target gene is repaired with
opposing bias, indicating high target sequence depen-
dency and in this case a low GC content in the flanking
region favoring correction of the non-transcribed strand
[51]. The specific repair mechanism underlying ssODN-
mediated TGA is still disputed. However, a general con-
sensus on the suppressive role of the MMR pathway has
been established with several groups reporting a correc-
tion efficiency increase in Msh2-deficient cells
[12,14,47,52,53]. The reason for this is not yet eluci-
dated. However, Msh2 is known to suppress homeolo-
gous recombination, i.e. HR between nearly homologous
sequences, potentially by functioning as an anti-recom-
binase - a phenomenon known as heteroduplex rejection
[54,55]. On the basis of this, the Msh2 protein has been
suggested to block ssODN-DNA heteroduplex formation
at the replication forks because of the sequence diver-
gence present here [14,54]. Likewise, cells lacking the
mismatch repair endonuclease Pms2 also showed a
higher level of ssODN-mediated TGA [46]. Recent
results show that the cellular introduction of ssODNs
leads to an increase in the amount of genomic DSBs
[12,48]. This indicates a genotoxic effect of ssODNs but
m o r en o t a b l yt h a tH D Rc o u l db ei n v o l v e di nt h eT G A
mechanism, despite the fact that ssODNs are comple-
mentary and not homologous to their target strands.
Likewise, the presence of these DSBs could explain the
aforementioned cell cycle arrest seen in ssODN-treated
cells with HDR-mediated repair causing arresting phos-
phorylation of cell cycle checkpoint proteins [12,41].
Besides the involvement of MMR and HDR, the NER
proteins, XPG and ERCC4 seems to be required to facil-
itate ssODN-mediated TGA, whereas components in the
NHEJ pathway was found to inhibit the correction pro-
cess [54,56]. The latter finding has been challenged
however, with recent data showing that ssODNs com-
pete for DSB-produced ends that would otherwise
engage in NHEJ [57]. Furthermore, it was shown that
single strand annealing (SSA) which is a repair pathway
correcting DSBs occurring between repetitive DNA
s e q u e n c e si sn o ti n v o l v e din ssODN-mediated TGA, as
otherwise described in yeast [57,58]. Recently, the invol-
vement of another DNA repair pathway, known as base
excision repair (BER), has also been implicated in
ssODN-mediated TGA by the use of methyl-CpG-modi-
fied ssODNs [30]. These oligonucleotides are able to
bind MBD4, a member of the BER pathway, and a gene
correction efficiency increase of more than 10-fold com-
pared to unmodified ssODNs was seen [30]. Methyl-
CpG-modified ssODNs are restricted by the necessity of
a guanine immediately 3’ o ft h eb a s et a r g e t e df o rr e p a i r
[30].
However, the ability to correct single-base mutations
without the incorporation of large pieces of exogenous
DNA has made ssODN-mediated TGA thoroughly stu-
died and employed in mammalian cells.
Chimeric RNA/DNA oligonucleotides (RDOs) are
another type of oligonucleotides which have been inves-
tigated for TGA. Compared to ssODNs, the RDO struc-
ture is more complex with a hairpin structure
comprising a DNA strand, homologous to the targeted
strand, pairing with RNA-nucleotides flanking the mis-
matched base [3]. The all-DNA strand of the RDO has
been shown to be the only active player in the TGA
process [59]. To avoid degradation of the RNA-moieties
by cellular nucleases these nucleotides are usually modi-
fied by 2’-O-methylation of the sugar units [60]. It is
believed that upon target invasion a heteroduplex is
formed causing cellular recognition of the newly formed
mismatch and leading to nucleotide correction using the
all-DNA RDO-strand as template [3]. RDOs are rarely
used in gene correction studies today, primarily due to a
lack of reproducibility of correction efficiencies
[2,3,41,51,54,60-62].
Small DNA-fragments
Small DNA-fragments (SDFs), also known as small
homologous DNA fragments, can be used for TGA. The
fragments usually comprise 400-1000 bp and are homo-
logous to their DNA target sequence being able to con-
currently modify up to 4 sequential basepairs in vitro as
well as in vivo [40,63]. SDFs induce genetic modification
by means of a homology-based mechanism known as
small fragment homologous replacement (SFHR)
[63,64]. The details of the SFHR mechanism are still
unknown [64]. However, homologous pairing is believed
to cause the endogenous DNA target sequence to be
replaced by the exogenous SDF after the introduction of
this fragment into the cell nucleus [63]. This replace-
ment causes a genetic modification of the targeted mis-
match. Surprisingly, the HDR repair pathway does not
seem to be directly involved in the SFHR-mechanism.
This is based on the finding of SDF-corrected cells
expressing wildtype p53, which normally inhibits homo-
logous recombination through binding of Rad51 and the
MRN complex [64,65].
SDFs can be created as either ds or ss DNA molecules
- the latter by heat-denaturation of the double-stranded
molecule [64]. Studies conducted using mammalian cells
indicate no difference in correction efficiency between
Jensen et al. Journal of Biomedical Science 2011, 18:10
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Page 6 of 14ss- and ds-SDFs [63,64]. However, a study carried out
using E. Coli indicates a higher efficiency using ss-SDFs
compared to ds-SDFs [35]. This may be due to circum-
v e n t i o no fa nS D Fu n p a i r i n gp r o c e s s ,w h i c hi nt h i s
study is suggested to be the rate-limiting step of the
bacterial SFHR process [35]. Like several other TGA
techniques including e.g. ODNs and TFOs (see below),
SDFs have shown relatively high correction efficiencies
within episomal target genes in vitro as well as in vivo
[4,8]. SDF-mediated episomal gene repair has been
reported in mouse embryonic stem cells and in human
hematopoietic stem/progenitor cells [8,38,40]. However,
the chromosomal correction efficiency obtained using
the SFHR method is decreased compared to ssODNs, as
opposed to the episomal repair efficiency [8]. The expla-
nation for this disparity could be the increased mobility
experienced by smaller molecules like ssODNs com-
pared to larger molecules, possibly facilitating increased
access to the nucleus [8]. In support of this notion we
found that SDFs were superior to ssODNs in the correc-
tion of a 1567G>A mutation in episomal b-galactosidase
genes (Figure 3). Furthermore, we used SDFs to correct
mutations in b-galactosidase genes in vivo in mouse
liver after hydrodynamic tail vein injection (unpublished
results). SDFs have also been successfully employed for
permanent ex vivo repair of the DNA-PKcs genes in a
SCID mouse cell line [63].
In order to increase the correction efficiency of SDFs,
ionizing radiation or treatment with Dox (doxorubicin),
which inhibits topoisomerase II, has been employed
[4,63]. The DSBs induced by these treatments are
known to activate endogenous repair pathways relying
on homologous recognition [4]. Besides Dox-treatment,
cellular treatment with phleomycin which is a DNA-
cleaving antibiotic able to cause S/G2 cell cycle shifts,
results in a 5-fold correction efficiency increase on chro-
mosomal targets [4]. This indicates SDF-mediated cell
cycle phase dependency as well as an involvement of
DNA replication in the SFHR mechanism, as reported
for ssODN-mediated TGA.
An advantage of SDF-mediated gene modification is
the reproducibility of results and no PCR artifacts
occurring with the concentrations of SDFs used to pro-
duce high correction efficiencies (0.2-10%) [38,40]. How-
ever, lack of knowledge on the mechanism underlying
SFHR and the error-prone PCR-based production
method limits the use of this technique.
Triplex-forming oligonucleotides (incl. peptide nucleic
acids)
Triplex-forming oligonucleotides (TFOs) and peptide
nucleic acids (PNAs) are single-stranded triplex-forming
molecules exhibiting target sequence complementarity
[66,67]. TFOs are short oligonucleotides (10-50 bp)
consisting of RNA, DNA or synthetic derivatives
(described later), which bind to the major groove of
duplex DNA [67]. Hereby, the TFO functions as a 3
rd
strand in a DNA-TFO-DNA triplex [67,68]. The specific
binding is limited to homopurine tracts of the target
sequence because the triplex is based on Hoogsteen
bonds which are dependent on the available H-bond
existing in purines [68,69].
Once bound to the targeted DNA, electrostatic repul-
sions originating between the TFO and DNA duplex are
believed to trigger an, as yet, unknown series of DNA
repair pathways [68,70]. The NER pathway has been
shown important for this repair process, with TFO-
mediated TGA not occurring in XPA- or CSB-depleted
cells [70,71]. Furthermore XPC/Rad23B has been shown
to recognize the TFO-induced triplex structure whereas
X P Da n dX P Fa r eb e l i e v e dt oc l e a v et h ed i s t o r t e dD N A
f o l l o w e db ys t r a n dr e - s y n t h e s i sb yP o l ζ (polymerase ζ),
which is involved in translesion bypass synthesis
[68,72,73]. NER as well as MMR has furthermore been
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Figure 3 Comparison between SDFs and ssODNs for correction
of 1567G>A mutations in b-galactosidase genes. CHO-K1 cells
were co-transfected with the pCH110 1567G>A plasmid and
correcting ssODNs (0.25 μM) or SDFs (7.5 nM) using 15 μg
Lipofectamine (Invitrogen) [51]. Two days after transfection b-
galactosidase enzyme activity was measured using a b-Galactosidase
Enzyme Assay system (Promega) according to the manufacturer’s
protocol. ssODNs were designed to target the antisense strand (AS)
of the b-galactosidase sequence in the region of the 1567G>A
mutation. Two different lengths were employed: 25nt (AS-ssODN,
25nt) and 35nt (AS-ssODN, 35nt), both containing a centrally located
cytosine in order to induce a mismatch with the targeted DNA. A
Cy3-conjugated ssODN (AS-ssODN, 35nt, Cy3-conjugated) was
included to test the effect of additional 5’-end protection. SDFs
were synthesized using the pCH110 659G>A plasmid as template as
previously described. The 480 bp SDF-molecule contained the
mismatched base 270 bp from the 5’-end. As negative controls
pCH110 1567G>A plasmid alone, a non-correcting SDF (constructed
using the pCH110 1567G>A plasmid as template) and SDF without
plasmid transfection were used.
Jensen et al. Journal of Biomedical Science 2011, 18:10
http://www.jbiomedsci.com/content/18/1/10
Page 7 of 14implicated in TFO-mediated TGA by the use of TFOs
conjugated with the phototoxic mutagen psoralen. These
modified TFOs induce TFO-directed psoralen interstrand
crosslinks (Tdp-ICLs) which seem to be recognized by a
multimeric complex consisting of either XPA-RPA
(NER) and MutSb (MMR) or XPC/Rad23B (NER) alone
[16]. These results have lead to the proposal of TFO-
mediated repair via an MMR-dependent error-free path-
way as well as an NER-mediated error-prone pathway
[16,74]. Furthermore, addition of TFOs along with a tar-
get-homologous DNA donor causes an increased gene
correction efficiency leading to suggestions on the invol-
vement of recombinatory repair pathways as well [75].
NHEJ is suggested to take over repair of Tdp-ICLs when
NER factors are absent, whereas the necessity of Rad51
for TFO-induced recombination implicates HDR in
TFO-mediated TGA [68,71]. In addition, a repair
mechanism shift exist between longer (~30nt) and
shorter (~10nt) TFOs with longer ones being repaired by
NHEJ and shorter ones by NER [68,76].
Synthetic derivatives of nucleic acids used to create
modified TFOs include methylene or ethylene bridged
2’-O, 4’-C’s of the TFO backbone. These are known as
bridged/locked nucleic acids (BNA/LNA) and ethylene
nucleic acids (ENA), respectively, and are able to
increase stability as well as correction efficiency under
various physical conditions [77-79]. However, LNA-
modified TFOs has yet to show a significant in vivo cor-
rection efficiency increase compared to unmodified
TFOs [4]. This, in addition to a restriction to homopur-
ine target sequences as well as weak DNA duplex bind-
ing at pH above 6, has made TFO-mediated TGA a
subject for optimization [4,69,77,78].
PNAs provide a functional alternative to TFOs and are
12-18 nucleotides with a DNA backbone completely
substituted by uncharged N-(2-aminoethyl)-glycine poly-
amides [80]. This modification highly increases the sta-
bility of the molecule through nuclease and protease
resistance [80]. Furthermore, it enables a stable complex
formation with the target DNA because of no electro-
static repulsions between the molecules [68]. This stabi-
lity can be further enhanced by PNA-conjugation of the
DNA intercalator molecule, 9-aminoacridine [81].
PNAs exist as three different variants: PNA oligomers,
bis-PNAs and pseudo-complementary PNAs (pcPNAs)
[66,82]. PNA oligomers can engage in either DNA-
PNA-DNA triplexes like TFOs or in a PNA-DNA-PNA
triplex invasion complex with the second DNA strand
displaced as a P-loop [83]. Both of these complexes
depend, at least partly, on Hoogsteen bonds causing a
similar restriction to homopurine tracts as seen with
TFOs. Likewise, bis-PNAs (2 PNA oligomers connected
by a linker) induce PNA-DNA-PNA triplex invasion
complexes [80]. These molecules have been shown to
successfully correct a b-globin splice site mutation in
primary hematopoietic progenitor cells [66]. However,
target restriction to homopurine tracts is considered to
be a major drawback of the triplexing method. Thus,
double-duplex forming pcPNAs are the primary mole-
cules used in PNA-mediated TGA today.
In pcPNAs, A and T nucleobases of the backbone
have been replaced with pseudo-complementary 2,6-dia-
minopurine (D) and 2-thiouracil (Us) bases, respectively
[84]. This incorporation sterically inhibits the otherwise
stable PNA-PNA duplex formation and results in a dou-
ble duplex invasion complex with the targeted DNA
[69]. This type of invasion is solely dependent on
Watson-Crick base pairing exempting pcPNAs from the
homopurine target restriction [67]. Using N-(ami-
noethyl)-D-lysine entities the pcPNA backbone can be
positively charged resulting in stable DNA duplex inva-
sion complexes because of the electrostatic attraction
between pcPNA and target [84]. The induced polarity
furthermore enables invasion of G-C rich target
sequences, which has otherwise been complicated by the
lack of pseudo-complementary G-C nucleobases [84].
The modification has resulted in episomal correction
frequencies of 0.65% [69]. However, the target sequence
is still required to contain ≥50% A-T’s in order to avoid
PNA-PNA duplex formation [67]. Histone deacetylase
(HDAC) inhibitor treatment following S-phase synchro-
nization has furthermore lead to chromosomal correc-
tion efficiencies of 0.78% indicating a role for DNA
replication in the mechanism of pcPNA-mediated TGA
[69]. The uncertainties concerning the TFO-mediated
repair mechanism apply for PNA-based technology as
well, with the mechanism employed by these techniques
believed to be similar, if not identical [69]. Since this
mechanism has yet to be elucidated the use of pcPNAs
for TGA is still not fully exploited.
Adeno-associated virus vectors
Targeted gene alteration using vectors based on adeno-
associated viruses (AAVs) has been studied for more
than a decade. AAVs are icosahedral viruses consisting
o fa4 . 7k bs i n g l e - s t r a n d e dg e n o m ee n c o d i n gr e p -a n d
cap-genes important for viral replication and capsid for-
mation, respectively [85]. These genes are flanked by
two inverted terminal repeats (ITRs, 145nt each), which
are cis-acting elements necessary for viral transduction
and functionality in TGA. The ITRs are the only origi-
nal viral elements present in recombinant AAV vectors
(rAAV), where rep- and cap-genes have been replaced
by the homologous target-specific DNA before cellular
introduction [4]. For production of the viral vectors the
rep- and cap-genes are provided in trans.
After entry of the vector into the cell, target-specific
homologous DNA is believed to activate and recruit
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MRN complex as well as Rad51 and Rad54 [86]. How-
ever, as described earlier, mammalian NHEJ is predomi-
nant compared to HDR for which reason homologous
recombination is fairly undermined [31]. This is an
obstacle that must be overcome since gene targeting is
only seen when the DNA donor is enrolled in the HDR
pathway. For this reason, several groups have studied
transient knock-down of one or more protein factors
known to be involved in the NHEJ pathway and this
with success. By creating heterodimeric Ku70
+/- cells
and using Ku70siRNA, it has been possible to increase
gene targeting frequency at a chromosomal locus almost
9-fold [31]. Likewise, transient depletion of Ku70 and
XRCC4, the latter being part of the XRCC4-LigIV com-
plex responsible for NHEJ-mediated ligation, created an
11-fold increase in HDR-mediated repair [32]. However,
a major restriction to the use of AAV vectors for TGA
is the high ratio of random integrations (RI) to targeted
HDR events seen in mammalian cells [5,87,88]. The
transient knock-down of Ku70 did not appear to affect
the RI frequency and with NHEJ believed to be the
cause of RI, these results indicate the existence of a
Ku70-independent NHEJ-pathway [31]. An alternative
NHEJ-pathway (A-NHEJ) has indeed been reported,
functioning in lymphoid cancers and being independent
of Ku70 and XRCC4 as well as other important NHEJ-
related factors [89]. However, the simultaneous deple-
tion of Ku70 and XRCC4 caused a decrease of RI,
s u g g e s t i n gt h a tX R C C 4m a ys i m p l yb em o r ep i v o t a l
than Ku70 in NHEJ-directed RIs [32].
As seen with SDFs [63], the introduction of DSBs as
well as SSBs following the transduction process has
demonstrated a significant increase in AAV-mediated
correction efficiency reaching levels as high as 65%
[88]. This increase supports the involvement of HDR
and NHEJ in AAV-induced genetic correction.
Furthermore, S-phase dependency seems important
with the S/G2-arresting drug phleomycin leading to a
10-fold increase in the chromosomal correction effi-
ciency of AAVs [4]. A direct correlation between intra-
cellular AAV copy numbers and gene targeting
frequency has been confirmed [11]. An advantage of
AAV-based TGA is the success with which mesenchy-
mal, hematopoietic and embryonic stem cells as well
as induced pluripotent stem cells have been genetically
targeted - with correction efficiencies ranging from
0.07-1% [90-93]. However, despite most groups only
reaching stem cell efficiencies around 0.01-0.1%, the
potential use of this technique to modify stem cells is
revolutionary [5,11,91]. Based on high fidelity gene tar-
geting, lack of pathogenicity and efficient in vivo deliv-
ery, AAV-mediated TGA shows great promise for the
future.
Zinc-finger nucleases
Zinc-finger nucleases (ZFNs) can be used for highly effi-
cient TGA in mammalian episomal as well as chromoso-
mal loci [13,94,95]. ZFNs are created by the fusion of 3-4
zinc-finger domains (ZFs), arranged in a bba-fold coordi-
nated by Zn
2+, with the non-specific DNA-cleavage
domain of the type IIS restriction enzyme, FokI [6,96,97].
Target specificity is determined by the amino-terminal
end of the ZFs involved, and with the re-engineering of
these domains, amino acid composition can be modified
to induce highly specific ZFN-target binding [98]. The
central feature of this technique is to induce DSBs in the
DNA target which is done by dimerization of the FokI
nuclease domains [99,100]. Therefore, ZFNs are pro-
duced in pairs with the FokI domains dimerizing at palin-
dromic target sequences [10,99]. The ZFNs are designed
to bind the targeted sequence in opposite directions
recognizing a total of 18-24 bp [101]. This specificity
ensures that only the targeted DNA sequence will be
bound considering the size of the mammalian genome
[102]. By supplying the ZFN pair to cells, genetic disrup-
tion is obtained by a FokI-facilitated DSB, which most
likely is repaired by the NHEJ pathway resulting in per-
manent damage to the inflicted gene [103]. Conversely,
if a DNA donor is simultaneously supplied to the
ZFN-targeted cells genetic correction of the targeted
sequence, through the activation of HDR, is achieved
with HR of target and donor DNA [13].
The use of ZFNs for genetic correction has proven to
be highly proficient with somatic gene correction effi-
ciencies of ~18-30% being repeatedly reproduced and
with human embryonic as well as hematopoietic stem
cells being successfully targeted [6,13,95,104]. Surpris-
ingly, the genetic correction of human CD34
+ hemato-
poietic progenitor cells has exhibited relatively low
efficiencies (0.11%) compared to stem cells [13]. This
divergence may be caused by poor growth as single
cells, an ability necessary for specialized selection [95].
Furthermore, the lack of a single construct harboring
the ZFN pair as well as the donor DNA might contri-
bute to the low correction efficiencies due to complica-
tions concerning multiple transductions of progenitor
cells [13,105]. Recent results show, however, that an
optimal ratio between donor DNA and ZFNs is crucial
to the gene correction efficiency in primary and adult
fibroblasts as well as murine ES cells and primary astro-
cytes [106]. A donor DNA:ZFN ratio of at least 10:1 was
shown necessary for optimal correction, indicating the
importance of separate constructs harboring the ZFN
pair and the donor DNA [106]. With the induction of a
DSB near t h es i t eo fm u t a t i o n ,t h eh i g h e s tZ F N -
mediated correctional efficiencies are reached - as seen
with SDFs and AAVs [63,88,107]. In cases where design-
ing a ZFN binding at the vicinity of the genomic
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tantly stimulated [102]. ZFNs inducing HR at a distance
of 400 bp has been successfully employed - however, at
a decreased recombination frequency [102].
Promising results have been obtained using an inte-
grase-defective lentiviral vector (IDLV) delivery method
for ZFNs with somatic correction efficiencies reaching
29% [13]. However, these results were questioned due to
the lack of southern blot analysis eliminating potential
RIs of the donor DNA as well as documenting the
actual HR process [95,108,109]. Random integration of
IDLVs in the human genome has likewise been detected,
posing a serious risk of unintended genetic modification
[13,110]. Likewise, the extent of ZFN-mediated geno-
toxicity is still unresolved. A decreased phosphorylation
of the mammalian damage sensor protein H2AX in
ZFN-corrected cells compared to ssODN-treated cells
indicates a tolerable level or complete lack of ZFN-
induced genomic damage [12]. These results are further
exciting due to the evidence of no misintegration of the
donor DNA plasmid as well as no gross chromosomal
rearrangements following ZFN-mediated genetic correc-
tion [6]. However, this conclusion could be challenged
by reports of high frequencies of off-target cleavages by
the ZFN pair, most likely caused by homodimerization
of the individual ZFN-FokI domains [99,102]. The pro-
blem may be solved by the addition of positive or nega-
tive charges to the individual ZFN during the
construction of these, causing electrostatic repulsion
among identical ZFNs [10,96,99]. Experiments per-
formed using this type of charged ZFNs shows a 40-fold
reduction in off-target cleavages whereas arresting the
targeted cells in the G2/M phase increased the HR:RI
ratio almost 6-fold [99,111]. Shortening the half-lives of
ZFN molecules by adding an N-terminal arginine
resulted in reduced genotoxicity without decreasing the
targeting efficiency [112]. Other factors affecting ZFN-
mediated genotoxicity are the number of ZFs used with
4 being less toxic than 3, and the length of the ZF-FokI
peptide linker with 4 amino acids being superior to 6
[102,113].
The construction of the complex ZFN molecules has
earlier posed a major drawback to the use of these for
genetic modification [114]. Originally, the ZFNs were
constructed by the use of a modular assembly-method
which encompasses the fusion of individual ZFs with
established DNA-binding specificities [115]. Despite the
relative ease with which this is performed, the efficiency
of creating a functional ZFN pair is extremely low (<6%)
[114,115]. However, with the construction of the publi-
cally available platform OPEN (Oligomerized Pool ENgi-
neering) the design of ZFNs has become easier as well
as safer [114,115]. Currently, the development of the
ZFN-based technique is influenced by extensive
patenting complicating the progression of the technique
[94]. But with initiatives like the Zinc Finger Consor-
tium providing public access to information concerning
Z F Nc o n s t r u c t i o na sw e l la se x p i r a t i o no fp r e d o m i n a n t
patents, this area is under constant development [114].
Conclusion
The ability to correct genomic mutations and repairing
cellular defects has been the centre of extensive research
for several decades. Successful studies have been made
with the transfer of full-length genes, but a constantly
emerging problem concerns the regulatory elements of
the gene of interest. However, this problem has been
circumvented with the emerging of targeted gene altera-
tion, which is based on the stimulation of endogenous
cellular repair mechanisms, i.e. no interfering with any
regulatory elements whatsoever. Targeted gene altera-
tion functions via the addition of a variety of oligonu-
cleotides including single-stranded oligonucleotides,
small DNA fragments, pseudo-complementary peptide
nucleic acids, adeno-associated virus vectors and zinc-
finger nucleases. The former techniques rely on target-
complementary oligonucleotides constructed by the use
of standardized or synthetic nucleic acids. They have
mainly received attention due to the ease and low cost
with which they are synthesized as well as the stability
of the molecules. However, gene correction efficiencies
have generally been low in somatic cells (0.1-20%) and
extremely low in various stem cells (~0.1%). Further-
more, the lack of knowledge concerning the different
genetic repair mechanisms stimulated by one of these
methods complicates optimization of the techniques.
Conversely, the latter techniques are based on target-
homology and stimulate genetic repair efficiency by the
activation of the homology-based repair mechanism,
HDR. However, the error-prone NHEJ is an unwanted
side effect of this stimulation for which reason focus has
been put on the cellular shut-down of this pathway in
order for HDR to dominate. This has proven to be suc-
cessful and AAVs and ZFNs obtain gene correction effi-
ciencies as high as 65% in somatic cells and 5% in stem
and progenitor cells. Despite their difficulty in synthesis
and potential safety concerns regarding viral pathogeni-
city these techniques appear very promising for future
studies on targeted gene alteration.
In this article, we have reviewed the methods currently
used in targeted gene repair and the underlying
mechanisms. Although clinical gene therapy has been
undergoing extensive progress within the last two dec-
ades, gene repair for clinical applications is still in its
infancy. The level of chromosomal gene correction effi-
ciencies has, until recently, been too low for clinical
translation. The key to enhanced gene correction effi-
ciency currently lies with an in-depth understanding of
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ferent TGA techniques. Furthermore, development of
robust assays to compare the efficiencies is necessary.
Efficient gene correction in progenitor cells is required
to permanently correct heritable genetic diseases. The
rapid evolution of efficient methods for generating pluri-
potent stem cells and improved ex vivo culture methods
will certainly improve our possibilities. Furthermore, the
development of Zinc-finger nucleases and the use of
adeno-associated virus vectors for gene repair have
made it possible to induce efficient gene correction both
in vitro and in vivo. This certainly has shortened the
distance to clinical trials. However, safety issues con-
cerning ZFN-mediated genotoxicity, off-target cleavages,
AAV-based viral concerns and random integrations still
remain to be solved, but high throughput sequencing
methods to check the outcome of the repair efforts are
already available. Thus, we are not in doubt that clinical
applications of gene repair techniques have a great
future - initially for monogenic disorders.
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